Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Group 1 - Novo Nordisk intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy to compete with Eli Lilly's Zepbound [1][2] - The high-dose Wegovy is expected to offer similar weight-loss potential as Zepbound, providing patients with an additional treatment option [3] - Novo Nordisk presented data from a sub-analysis of the phase 3 REDEFINE 1 trial, showing cagrilintide's efficacy in achieving significant weight loss [4][5] Group 2 - The phase 3 RENEW program will investigate the efficacy and safety of cagrilintide in individuals with obesity or overweight, set to start in Q4 2025 [6] - Novo Nordisk is undergoing a significant restructuring plan, cutting 9,000 jobs, which is 11.5% of its workforce, aiming to save approximately $1.3 billion annually [7] - Following the restructuring announcement, NVO stock increased by 2.93% to $57.25 [7]